Mechanisms of vascular damage in systemic sclerosis (Q37622943)

21 August 2017

1 reference

title

Mechanisms of vascular damage in systemic sclerosis (English)

1 reference

21 August 2017

1

Ulf Müller-Ladner

1 reference

21 August 2017

3

Lidia Ibba-Manneschi

1 reference

21 August 2017

Oliver Distler

2

1 reference

21 August 2017

Elena Neumann

series ordinal

4

1 reference

21 August 2017

Steffen Gay

series ordinal

5

1 reference

21 August 2017

publication date

1 November 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

42

1 reference

21 August 2017

issue

7

1 reference

21 August 2017

page(s)

587-595

1 reference

The pathology of scleroderma vascular disease

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Vascular complications of scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Genetic basis for systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Epigenetic regulation of vascular endothelial gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Role of PDGF in fibrotic diseases and systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Physiologic responses to hypoxia and implications for hypoxia-inducible factors in the pathogenesis of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Endothelin is a downstream mediator of profibrotic responses to transforming growth factor beta in human lung fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Expression and function of ETA and ETB receptors in SSc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Amelioration of cyclosporin A effect on microvasculature by endothelin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Functional autoantibodies, a new paradigm in autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Pulmonary arterial hypertension related to systemic sclerosis in 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Thromboxane synthetase inhibition in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Raynaud's phenomenon of the lung. A reality both in primary and secondary Raynaud syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Circulating endothelial progenitor cells in systemic sclerosis: association with disease severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Treatment of pulmonary arterial hypertension due to scleroderma: challenges for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Local implantation of autologous mononuclear cells from bone marrow and peripheral blood for treatment of ischaemic digits in patients with connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/08916930903002487

10.1080/08916930903002487

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference